Transient HIV-specific T cells increase and inflammation in an HIV-infected patient treated with nivolumab

AIDS | April 24, 2017

Gwenaelle Le Garff,, Assia Samri, Sidonie Lambert-Niclot, et. al.
DOI: 10.1097/QAD.0000000000001429

Download the paper


Immune checkpoint inhibitors (ICIs) can reverse T-cell anergy and boost immune responses against tumours. Nivolumab, an ICI directed against programmed death-1 (PD-1), has become the new standard of care for second-line treatment of advanced nonsmall cell lung cancer (NSCLC) [1–3]. It is thought to be an even clever therapeutic option in HIV-infected patients, as the overexpression of PD-1 on exhausted HIV-specific T cells allows ICIs to reactivate PD-1+ T cells and to improve HIV-specific immune responses.